---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39890271.md"
description: "$XTALPI(02228.HK) In January of this year, the FDA received a letter of intent for the liver organ-on-a-chip ISTAND program led by the 3Rs Collaborative. In that long list of participants—Axiom/LifeNet Health, BioIVT, CN Bio, DefiniGEN, TissUse...Xellar (Yaosu Technology) is the only Chinese organ-on-a-chip company selected. The more you look into this company, the more interesting it gets. As Xie Xin said: In the future, our technology platform is expected to directly enter the IND application system and become a standard tool in the new drug R&D process."
datetime: "2026-04-14T06:57:09.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39890271.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39890271.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39890271.md)
author: "[wolf-001](https://longbridge.com/en/profiles/15460724.md)"
---

# $XTALPI(02228.HK) In January of this year, the FDA…


### Related Stocks

- [02228.HK](https://longbridge.com/en/quote/02228.HK.md)

## Comments (6)

- **周树人的交易员 · 2026-04-14T07:00:26.000Z · 👍 1**: Mr. Wolf has been frequently exposing Yaosu recently, which is quite rare.
  - **江汉南京** (2026-04-14T07:13:05.000Z): Boss Zhou has been rarely seen online recently.
  - **江汉南京** (2026-04-14T07:13:33.000Z): I feel that Mr. Li is also a talent in the tech company.
  - **周树人的交易员** (2026-04-14T07:14:51.000Z): Nothing to say, waiting for more activity below 8.8